Connect Biopharma Holdings Limited · NASDAQ:CNTB
Connect Biopharma — Leerink Conference February 2022
6 slides from Connect Biopharma's conference presentation, Feb 16, 2022
Slide 1: Leerink Conference Presentation – February 2022
Leerink Conference Presentation – February 2022 NASDAQ: CNTB DEVELOPING NEXT-GENERATION THERAPEUTICS FOR T CELL DRIVEN INFLAMMATORY DISEASES Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation regarding Connect Biopharma Holdings Limited ("Connect," "we," "us" or "our") has been prepared solely for informational purposes. Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data
Slide 3: Company Highlights
Validated, T cell-modulating discovery approach designed to enhance and speed up the identification of potentially highly differentiated immune modulators CBP-201:- Interleukin-4-receptor alpha (IL4Ra) blocker CBP-307:- Sphingosine 1-phosphate-1 (S1P1) modulator CBP-174:- Peripherally acting Histami
Slide 4: Key Accomplishments in 2021
Key Accomplishments in 2021 Completed IPO in Q1’21 ($220M proceeds) Completed CBP-201 Global Ph2b in adult AD patients Completed enrollment of CBP-307 Ph2 in UC Initiated Global Ph2 trial for CBP-201 in Asthma and NP Initiated pivotal Ph2/3 trial for CBP-201 in China in AD Initiated Ph1 trial for CB
Slide 5: A pipeline of potentially highly differentiated therapies
A pipeline of potentially highly differentiated therapies Connect Biopharma has Global Development & Commercialization Rights to all Product Candidates INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NEXT ANTICIPATED MILESTONE CBP-201 Antibody targeting IL-4Rα cytokine receptor (Th2 cell modulator) A
Slide 6: NASDAQ: CNTB
NASDAQ: CNTB
Connect Biopharma Holdings — Leerink Conference February 2022 on 6ix